TET3 facilitates bladder cancer progression through targeted modulation of stemness pathways

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Bladder cancer necessitates understanding molecular drivers for effective therapy.
• The role of TET3 (ten-eleven translocation 3), a DNA hydroxymethylase, in bladder cancer is not well understood.
• Identifying key regulators is crucial for targeted treatment strategies.

Purpose of the Study:

• To investigate the role and mechanism of TET3 in bladder cancer progression.
• To evaluate TET3 as a potential therapeutic target and prognostic marker.

Main Methods:

• Analysis of single-cell RNA sequencing data to identify TET3 in tumor-promoting cells.
• Functional assays including TET3 knockdown, in vivo tumor growth, and sphere formation assays.
• Assessment of stemness-associated gene expression (SOX2, NANOG) and DNA 5-hydroxymethylation (5hmC) levels.

Main Results:

• TET3 is highly expressed in bladder tumor-promoting cells.
• TET3 knockdown significantly inhibited cell proliferation, migration, and in vivo tumor growth.
• TET3 knockdown reduced stemness markers (SOX2, NANOG) and sphere formation, impairing cancer cell self-renewal.
• TET3 regulates key tumor-related genes/pathways and affects DNA 5hmC levels.

Conclusions:

• TET3 promotes bladder cancer growth and progression by modulating the cancer stemness pathway.
• TET3 plays a critical role in maintaining cancer cell stemness and self-renewal capacity.
• TET3 represents a promising therapeutic target and prognostic marker for bladder cancer.